About us
Our team
Our science
Radiopharmaceuticals
Our technology
Abstracts & publications
Our pipeline
News
All news
ASX releases
Media releases
Investors
Share price
Annual reports
Shareholder newsletter
Analyst coverage
Corporate governance
Corporate policies
Contact us
About us
Our team
Our science
Radiopharmaceuticals
Our technology
Abstracts & publications
Our pipeline
News
All news
ASX releases
Media releases
Investors
Share price
Shareholder newsletter
Analyst coverage
Corporate governance
Corporate policies
Contact us
News
ASX Releases
May 29, 2023
FDA Pre-IND Meeting Supports an IND Application for RAD101
Read more
Read more
May 9, 2023
RAD Receives FDA Orphan Drug Designation for Trivehexin (RAD301) in Pancreatic Cancer
Read more
Read more
April 17, 2023
RAD Enters into Supply Agreement with Terthera for Terbium-161 Isotope
Read more
Read more
March 28, 2023
RAD Invited to Participate in Jefferies Radiopharma Innovation Summit
Read more
Read more
March 28, 2023
RAD Receives $1.56M R&D Tax Incentive
Read more
Read more
March 27, 2023
RAD and GenesisCare Partner to Develop Novel Radiopharmaceuticals in Australia
Read more
Read more
Load More
MEDIA releases
July 8, 2022
RAD to Start Prostate Cancer Trial, Interview with Financial News Network
Read more
Read more
June 28, 2022
World Congress Trivehexin Poster Presentation Shows Encouraging Integrin Data
Read more
Read more
May 18, 2022
CEO Riccardo Canevari Updates Investors and Discusses Licensing of a Asset from UCLA
Read more
Read more
May 9, 2022
Radiopharm Theranostics panel discusses latest progress and understanding of the radiopharmaceutical sector
Read more
Read more
May 6, 2022
Radiopharm continues strong progress and recognition of AVβ6-Integrin in Europe
Read more
Read more
April 4, 2022
CEO Riccardo Canevari visits Sydney and discusses the use of radiopharmaceuticals with Financial News Network
Read more
Read more
Previous
Load more
Sign up to our mailing list.
Receive all the latest news from Radiopharm Theranostics.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please fill out all starred fields.